Navigation Links
Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
Date:11/13/2012

ain the properties of conventional, non-fused antibody therapeutics in stimulating ADCC and complement-dependent cytotoxicity (CDC) functions.  Such mAb-IFN fusion proteins have demonstrated superior efficacy and safety in preclinical studies, validating the therapeutic potential of this technology.

About ImmunGene Inc.

ImmunGene is a privately held biotechnology company focused on the development of monoclonal antibody-based therapies for the treatment of cancer. ImmunGene has several programs at various stages of the development. In addition, the company has developed proprietary antibody-cytokine fusion technology comprised of highly potent cytokines and stable linkers for genetically attaching the cytokines to monoclonal antibodies. ImmunGene has an exclusive license on the antibody-cytokine fusion protein technology developed by Professor Sherrie Morrison at UCLA.  More information can be found at: www.immungene.com.

About Caliber Biotherapeutics, LLC

Caliber Biotherapeutics, LLC is a biotechnology company based in Bryan, Texas with a mission to develop and commercialize protein-based therapeutics that improve outcomes for patients with cancer and other diseases. The Company utilizes technological innovations in biological research, product development and manufacturing to create treatments with increased safety and effectiveness--while reducing both costs and development time.  Caliber has created a rich pipeline of monoclonal antibody-based products, including biobetter product candidates applying its expertise in the Nicotiana benthamiana plant-based expression and manufacturing of recombinant proteins. Caliber operates the world's largest N. benthamiana expression based protein manufacturing facility in College Station, Texas. Caliber's technologies are being supported by the Cancer Prevention and Research Institution of Texas (CPRIT), DARPA and several Texas ba
'/>"/>

SOURCE Valor Biotherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Caliber IDs VivaScope technology found to be 100% sensitive for basal cell carcinoma diagnosis
2. Caliber Imaging & Diagnostics Releases New Products for Noninvasive, Rapid Imaging of Living Cells
3. Lucid, Inc. Reflects New Vision with Name Change to Caliber Imaging & Diagnostics, Inc.
4. AdvaMed Launches MVP Mentoring Portal for Veterans
5. SafeCode Drug Technologies Launches New Website With Product Video Demonstrating the Worlds Next Generation Application for Drug Safety Administration
6. AASLD Curriculum & Training (ACT) Launches With New Interactive HCV Education
7. Sarnova Launches Curaplex Private Label Brand
8. Zimmer Launches Smartphone Comeback App Globally
9. 3rd Annual National Event to Raise Awareness of Prescription Drug Abuse Launched
10. CVS/pharmacy to Launch Flu Shot Donation Campaign Benefiting the USO During Week of Veterans Day
11. QIAGEN Kicks Off Next-Generation Sequencing Initiative With Launch of a Series of Consumable Products to Improve NGS Workflows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... IRVINE, Calif. , July 30, 2015 /PRNewswire/ ... Novartis /Alcon executives have recently contacted the Company ... will begin as early as Monday, August 3, ... been quoted as saying that the coming electronic ... billions of dollars over the next several years.  ...
(Date:7/30/2015)... 30, 2015  Unichem Pharmaceuticals ( USA ... Hydrochlorothiazide tablets 25 mg 1000-count bottle to the consumer ... measure due to the identification of a Clopidogrel tablet ... The risk associated with mistakenly taking a Clopidogrel ... probability of experiencing Clopidogrel,s side effects which include bleeding ...
(Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) ... of 2015. Key results include: , Total ... of 2014 to $5,370 million, with 6 percent ... (etanercept), Prolia ® (denosumab), Sensipar ® ... ® (denosumab). Unfavorable changes in foreign exchange ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
(Date:7/31/2015)... ... July 31, 2015 , ... That’s right, ... are the STASH awards? The Significant Technological Achievements in Secretive Horticulture (or STASH) ... well as tried-and-true products that have stood the test of time. These include ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reliable source ... in Chicago at Grant Park. The festival will end on Sunday, August 2nd. ... Chicago for the annual Lollapalooza. This unique and unbelievably popular festival attracts the ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival ... Zeltiq Aesthetics released this new applicator in the United States as an upgrade to ... thighs. The original applicator required a 2 hour treatment time. The new ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of ... three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology ... from MDLinx makes preparing for the exam easy and painless. MDLinx offers thousands ...
(Date:7/31/2015)... New York (PRWEB) , ... ... ... trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now ... 28th, 2015 was well received with a 94% approval rating from the ...
Breaking Medicine News(10 mins):Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2
... As population ages, even small changes affect incidence, ... lifestyle factors affect older adults, risk of diabetes, a ... link between lifestyle and incidence of diabetes over 10 ... older. The lifestyle factors examined included physical activity, dietary ...
... These Agents Will Face Greater Use of Step Therapy ... Health Plans, According to a New Report from HealthLeaders-InterStudy ... 28 HealthLeaders-InterStudy and Fingertip Formulary find ... expected to face tougher formulary restrictions. According to the ...
... Medical Record System Used by Health Clinics around the ... Prize for Software in the Public Interest has been ... work has made an outstanding contribution to the public ... Darius Jazayeri will be awarded today for his creation ...
... WHO: Myles Druckman, MD, a leading disease outbreak and pandemic, ... by, top-tier news outlets, including CBS ... Washington Post, about SARS, avian flu, and other, ... and associated topics, including:, ...
... VANCOUVER, April 28 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: ... today reported financial results for the first quarter ended ... in U.S. dollars and in accordance with U.S. GAAP. ... profitability, driven by our revenue streams from Visudyne(R) and ...
... to speak at Annual SALGBA meeting in Denver- ... productivity and methods for measuring the cost of ... environment impacts personal health- Insights into how to ... April 28 With ...
Cached Medicine News:Health News:Lifestyle Factors Tied to Older Adults' Diabetes Risk 2Health News:Fixed Dosed Combination Agents and Novel Antihypertensives Are Expected to Face Tougher Formulary Restrictions 2Health News:Fixed Dosed Combination Agents and Novel Antihypertensives Are Expected to Face Tougher Formulary Restrictions 3Health News:2009 Pizzigati Prize for Public Interest Computing Awarded to Darius Jazayeri 2Health News:2009 Pizzigati Prize for Public Interest Computing Awarded to Darius Jazayeri 3Health News:Available for Interviews: Pandemic, Disease Outbreak Expert to Discuss Swine Flu 2Health News:Available for Interviews: Pandemic, Disease Outbreak Expert to Discuss Swine Flu 3Health News:QLT announces first quarter results for 2009 2Health News:QLT announces first quarter results for 2009 3Health News:QLT announces first quarter results for 2009 4Health News:QLT announces first quarter results for 2009 5Health News:QLT announces first quarter results for 2009 6Health News:QLT announces first quarter results for 2009 7Health News:QLT announces first quarter results for 2009 8Health News:QLT announces first quarter results for 2009 9Health News:QLT announces first quarter results for 2009 10Health News:QLT announces first quarter results for 2009 11Health News:QLT announces first quarter results for 2009 12Health News:QLT announces first quarter results for 2009 13Health News:Alere's Dr. Michael Taitel Provides Insights Into Reducing Health and Productivity Costs During Turbulent Economic Times 2Health News:Alere's Dr. Michael Taitel Provides Insights Into Reducing Health and Productivity Costs During Turbulent Economic Times 3Health News:Alere's Dr. Michael Taitel Provides Insights Into Reducing Health and Productivity Costs During Turbulent Economic Times 4
The Trident ceramic acetabular system provides several important benefits and meets greater demands of younger, more active patients....
Optimal solution for normal acetabulum and younger patients....
The Biopro Cox comb cup is manufactured from titanium and is porous coated on the outside of the shell. The Cox comb cup accommodates a polyethylene insert....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
Medicine Products: